Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in biologic/targeted synthetic DMARD inadequate-response rheumatoid arthritis
jRCT2041210052Suspended
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Randomised, double-blind trial of ABBV-154 in rheumatoid arthritis (RA) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of participants achieving ACR50 response. Started Sep 2021; status: suspended.
02
Drugs
ABBV-154
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2041210052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210052.